Looking out over the past year, company shares have been recorded -38.47% off the 52 week high and 45.44% away from the low over the same period.Covering sell-side analysts have recently weighed in on shares of OncoSec Medical Incorporated (NASDAQ:ONCS). Analysts are projecting that the stock will reach $5.00 on a short term (1 year) basis. Dawson James reissued a "buy" rating and issued a $5.00 price target on shares of OncoSec Medical in a report on Thursday, July 6th. Maxim Group's price target would indicate a potential upside of 358.72% from the company's current price. Noble Financial reiterated a buy rating on shares of OncoSec Medical in a research note on Wednesday, June 14th. The stock boasts a consensus analyst "Buy" rating with the consensus recommendation standing at 2.00. Company shares have been seen trading -90.54% off of the 52 week high and 92.19% away from the 52 week low. HC Wainwright set a $6.00 price target on OncoSec Medical and gave the stock a "buy" rating in a report on Monday, June 12th. ValuEngine upgraded shares of OncoSec Medical from a strong sell rating to a sell rating in a research note on Friday, July 14th.
OncoSec Medical Incorporated (NASDAQ:ONCS) shares are moving 16.51% trading at $1.27 today. OncoSec Medical has an average rating of Buy and a consensus price target of $5.33. The value of the company's investment in OncoSec Medical Incorporated decreased from $1,255,000 to $1,152,000 a change of $103,000 quarter to quarter. Share performance for the month is now at 2.83%. The company's market cap is $20.96 million. The stock is trading at $1.09 significantly above the 50 day moving average of $0.99 and a tad above the 200 day moving average of $1.07. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and global copyright and trademark law.Читайте также: US Justice Department career staff would reportedly oppose T-Mobile-Sprint merger
OncoSec Medical Incorporated, launched on February 8, 2008, is a biotechnology company. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2017 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог